The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.

Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.

The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.

The firm will use the funding to advance ongoing clinical trials of its autologous cell therapies for solid tumors.

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.